Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytochrome P450 2D6 genotype and methadone steady-state concentrations.

C B Eap1, F Broly, A Mino

  • 1Département Universitaire de Psychiatrie Adulte, H pital de Cery, Prilly-Lausanne, Switzerland. Chin.Eap@inst.hospvd.ch

Journal of Clinical Psychopharmacology
|March 29, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Definition of treatment-resistant late-life depression: Conclusions from a European Task Force Delphi process.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Management of insomnia in inpatient psychiatric care: a clinical practice evaluation.

European archives of psychiatry and clinical neuroscience·2026
Same author

Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland.

Psychiatry research·2026
Same author

Clinical characteristics of depressed children and adolescents with and without suicidal thoughts and behavior: a cross-sectional study.

Frontiers in child and adolescent psychiatry·2025
Same author

Biopsychosocial risk factors for subjective cognitive decline among older adults during the COVID-19 pandemic: a population-based study.

Public health·2024
Same author

Safety and tolerance of combination of monoamine oxidase inhibitors and direct dopamine agonists in adults and older adults with highly resistant depression.

L'Encephale·2023

Cytochrome P450 2D6 genetic variations affect methadone metabolism and plasma levels in patients undergoing methadone maintenance treatment. Poor metabolizers showed higher (R)-methadone levels compared to ultrarapid metabolizers.

Area of Science:

  • Pharmacogenetics
  • Clinical Pharmacology

Background:

  • Cytochrome P450 2D6 (CYP2D6) exhibits genetic polymorphism, leading to distinct metabolic phenotypes: poor, extensive, and ultrarapid metabolizers.
  • Methadone maintenance treatment (MMT) is a cornerstone therapy for opioid dependence, with its efficacy influenced by individual drug metabolism.

Purpose of the Study:

  • To investigate the relationship between CYP2D6 genotypes and steady-state plasma concentrations of methadone enantiomers.
  • To assess the impact of CYP2D6 metabolic status on MMT outcomes, including illicit opiate use and withdrawal symptoms.

Main Methods:

  • Plasma levels of (R)-, (S)-, and (R,S)-methadone were measured in 256 MMT patients.
  • Patients were genotyped for CYP2D6 to determine their metabolic status (poor, extensive, or ultrarapid).

Related Experiment Videos

  • Medical records were reviewed to evaluate MMT success based on treatment adherence and symptom absence.

    • Main Results:

    • Significant differences in (R)-, (S)-, and (R,S)-methadone concentrations relative to dose-to-weight ratios were observed across CYP2D6 genotypes (p < 0.05).
    • (R)-methadone levels were significantly lower in ultrarapid metabolizers compared to poor metabolizers (p = 0.009).
    • While not statistically significant (p = 0.103), a higher proportion of poor metabolizers (72%) achieved successful treatment outcomes compared to ultrarapid metabolizers (40%).

    Conclusions:

    • CYP2D6 plays a significant role in the metabolism of methadone.
    • CYP2D6 ultrarapid metabolizer status may influence methadone pharmacokinetics, warranting further investigation into its impact on MMT efficacy.